文献速递妇产影像MR

MRI影像组学诺模图预测宫颈癌术后复发

AI-assisted Radiomic Model for Cervical Cancer Recurrence Prediction: A Multicenter Retrospective Study with Experimental Validation.
PubMed 文献 · Radiol Imaging Cancer · 2026-01-01

多中心回顾性研究纳入804例宫颈癌患者,从治疗前MRI肿瘤及瘤周5 mm区域提取三维影像组学特征,构建随机生存森林Radscore。联合FIGO分期、SCC抗原、SIRI与Radscore的诺模图在外部测试集中1、3、5年DFS的AUC分别为0.93、0.84、0.86。

要点

  • 诺模图联合临床、炎性指标与MRI影像组学,可无创预测宫颈癌术后DFS。
  • 治疗前MRI肿瘤及瘤周5 mm区域的影像组学特征具有预后价值。
  • 外部测试集中1年DFS预测AUC达0.93,短期复发预测效能较高。

核心结论

  • 整合临床-影像组学的诺模图可较准确无创预测宫颈癌患者术后复发。
  • 影像组学标签-TRIM29-细胞周期调控轴经转录组分析与体外实验验证。

研究设计与样本

  • 多中心回顾性研究,纳入804例宫颈癌患者,时间范围2016至2023年,中位随访43.7个月。
  • 临床预测队列751例,中位年龄52岁(IQR 47-58岁),随访期间164例(21.8%)出现复发。
  • 从治疗前MRI肿瘤与5 mm瘤周区域提取三维影像组学特征,测试五种机器学习算法构建Radscore。
  • 通过多变量Cox回归建立诺模图,并用生物信息学分析与体外实验验证生物学机制。

关键影像表现/征象

  • 治疗前MRI肿瘤与瘤周5 mm区域的影像组学特征用于构建生存预测模型。

诊断标准与关键数值

  • 随机生存森林影像组学模型在外部测试集中1、3、5年DFS的AUC分别为0.88(95% CI: 0.83, 0.94)、0.82(95% CI: 0.75, 0.90)、0.89(95% CI: 0.83, 0.95)。
  • FIGO分期、鳞状细胞癌抗原水平、全身炎症反应指数与Radscore被确定为DFS的独立预后因素。
  • 诺模图在外部测试集中1、3、5年DFS的AUC分别为0.93(95% CI: 0.90, 0.97)、0.84(95% CI: 0.78, 0.90)、0.86(95% CI: 0.80, 0.92)。

临床应用与阅片要点

  • 阅片时可关注治疗前MRI肿瘤及瘤周5 mm区域的影像组学特征,辅助评估宫颈癌复发风险。
  • 诺模图联合FIGO分期、SCC抗原与SIRI,适用于宫颈癌术后DFS的无创预测。
  • 短期(1年)复发预测效能高于中期(3、5年),报告中应结合临床指标综合判断。

局限性

  • 回顾性研究设计存在选择偏倚风险。
  • 影像组学特征的生物学机制验证依赖转录组分析与体外实验,体内可解释性仍有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate the value of a nomogram model incorporating clinical parameters, hematologic inflammatory biomarkers, and MRI radiomic features in predicting postoperative disease-free survival (DFS) in patients with cervical cancer and to explore the biologic mechanism underlying the radiomic signature. Materials and Methods This multicenter retrospective study enrolled 804 patients with cervical cancer (2016-2023), with a median follow-up of 43.7 months. Three-dimensional radiomic features were extracted from pretreatment MRI tumor and 5-mm peritumoral regions. Five machine learning algorithms were tested to construct the optimal radiomics score (Radscore). Multivariable Cox regression was used to develop the nomogram model, with bioinformatic analysis and in vitro experiments for biologic mechanism validation. Results In the clinical prediction cohort (n = 751; median age, 52 years [IQR, 47-58 years]), 164 patients (21.8%) experienced recurrence during follow-up. The random survival forest-based radiomics model achieved optimal predictive performance in the external test set, with 1-, 3-, and 5-year DFS areas under the receiver operating characteristic curves (AUCs) of 0.88 (95% CI: 0.83, 0.94), 0.82 (95% CI: 0.75, 0.90), and 0.89 (95% CI: 0.83, 0.95), respectively. International Federation of Gynecology and Obstetrics stage, squamous cell carcinoma antigen level, systemic inflammation response index, and Radscore were identified as independent prognostic factors for DFS, which were incorporated into the nomogram model, with 1-, 3-, and 5-year DFS AUCs of 0.93 (95% CI: 0.90, 0.97), 0.84 (95% CI: 0.78, 0.90), and 0.86 (95% CI: 0.80, 0.92) in the external test set. A radiomic signature-TRIM29-cell cycle regulatory axis was identified and validated via transcriptomic analysis and in vitro experiments. Conclusion The integrated clinical-radiomic nomogram developed in this study enables accurate noninvasive prediction of postoperative recurrence in patients with cervical cancer. Keywords: MRI, Machine Learning, Radiomics, Prognosis and Prediction, Cervical Cancer, Recurrence, Inflammatory Markers Supplemental material is available for this article. © RSNA, 2026.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Chen, Zhang, Chen, et al. AI-assisted Radiomic Model for Cervical Cancer Recurrence Prediction: A Multicenter Retrospective Study with Experimental Validation. Radiol Imaging Cancer. 2026. PMID: 42360142. doi:10.1148/rycan.250618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。